Avoid 483s & Warning Letters: Build a Solid FDA Inspection Strategy
Teams often feel confident in their systems until an FDA inspection exposes gaps that were not anticipated, such as missing documentation, incomplete training, or CAPA actions that were never fully closed. We see this frequently when organizations rely on reactive fixes instead of a structured readiness program. The difference between a clean inspection and a […]
Your Next FDA Inspection Is Closer Than You Think, Here’s How to Be Fully Prepared
FDA inspections can occur at any time. For Pharmaceutical, Biotech, and Medical device companies, maintaining continuous compliance is critical to protect operations, product quality, and patient safety. Unprepared organizations risk 483 observations, Warning Letters, and regulatory delays consequences that are costly both financially and reputationally. BioBoston Consulting helps companies stay inspection-ready every day, not just during scheduled audits. Why Continuous FDA Readiness Matters Inspection […]
Avoid 483s & Warning Letters: Build a Rock-Solid FDA Inspection Strategy
Teams often feel confident in their systems until an FDA inspection exposes gaps that were not anticipated, such as missing documentation, incomplete training, or CAPA actions that were never fully closed. We see this frequently when organizations rely on reactive fixes instead of a structured readiness program. The difference between a clean inspection and a […]